Viatris has secured a major regulatory milestone in East Asia as Japan’s Ministry of Health, Labour and Welfare (MHLW) officially approved Wakix, known generically as pitolisant. The oral therapeutic has been cleared to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea syndrome (OSAS), as well as narcolepsy types 1 and 2. This landmark decision introduces a first-in-class treatment mechanism to the Japanese pharmaceutical landscape, expanding options for patients struggling with chronic, debilitating sleep disorders.
The approval is a significant win for Viatris, which licenses pitolisant exclusively in Japan from its original discoverer, the French pharmaceutical company Bioprojet. Industry experts note that the inclusion of Wakix in Japan’s formulary addresses substantial unmet medical needs in sleep medicine, particularly because the drug operates via a novel biological pathway and is notably excluded from controlled substance classifications.
Comprehensive Scope of the Japanese Regulatory Approval
The newly granted MHLW approval is broad, targeting two distinct patient populations who often experience severe impairments in their daily functioning and quality of life. First, the indication covers adult patients diagnosed with OSAS who continue to experience persistent excessive daytime sleepiness despite receiving primary therapies aimed at alleviating upper airway obstruction, such as continuous positive airway pressure (CPAP) machines or surgical interventions.
Second, the approval encompasses narcolepsy, addressing both Type 1 narcolepsy—which is characterized by sudden episodes of muscle weakness triggered by strong emotions, known as cataplexy—and Type 2 narcolepsy, which presents without cataplexy. Historically, therapeutic options for these indications have relied heavily on traditional stimulants or compounds subject to strict regulatory controls due to risks of abuse, dependence, or tolerance.
Wakix stands apart as the first histamine H3 receptor antagonist and inverse agonist to receive regulatory clearance in Japan for these specific indications. By modulating the brain’s endogenous histaminergic system, the drug promotes wakefulness through a unique mechanism of action that avoids the physiological pitfalls commonly associated with traditional central nervous system stimulants.
Clinical Foundation and Regulatory Pathway
The Japanese approval of pitolisant was underpinned by a robust dossier of clinical data, combining domestic Phase III trials conducted specifically within Japanese patient cohorts with a vast body of international clinical research evidence. The bridging of domestic and global data demonstrated both the safety and efficacy of the compound across ethnically diverse populations, satisfying the stringent requirements of the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
Prior to receiving this full marketing authorization, pitolisant achieved an important regulatory status in Japan when it was granted orphan drug designation for the treatment of narcolepsy. This designation is typically reserved for pharmaceutical products intended to diagnose, prevent, or treat rare diseases that affect a limited patient population, providing developers with regulatory incentives and scientific advice.
Globally, pitolisant has already established a strong regulatory footprint. Wakix has secured marketing authorization for narcolepsy in more than 38 countries worldwide, including the United States and multiple nations across the European Union. Furthermore, its indication for OSAS-related excessive daytime sleepiness has been greenlit in over 29 European countries, reflecting a well-documented safety profile amassed over years of post-marketing surveillance and clinical application.
Executive Perspectives and Strategic Importance
Leadership at Viatris emphasized the strategic value of the approval, highlighting its alignment with the company’s broader objective of expanding its innovative medicines portfolio in key international markets.
Philippe Martin, chief research and development officer at Viatris, addressed the milestone in an official statement, noting the transformative potential of the therapy for Japanese healthcare providers and their patients. "As Japan’s first approved histamine H3 receptor antagonist/inverse agonist for these conditions, Wakix offers a much-needed novel treatment option for patients," Martin stated. He further underscored the clinical advantages of the drug, adding, "This milestone marks an important advancement for sleep medicine in Japan and brings forward a treatment option that is not classified as a controlled substance. We continue to strengthen Viatris’ innovative medicines portfolio in this strategically important market by investing in differentiated therapies for patients."
The inclusion of pitolisant reinforces Viatris’ commercial strategy in the region, focusing on differentiated, value-added medicines that address complex chronic conditions. The partnership with Bioprojet remains a cornerstone of this strategy, leveraging French scientific discovery through Viatris’ expansive global commercialization infrastructure.
Understanding the Mechanism and Clinical Differentiation
To fully appreciate the significance of Wakix’s entry into the Japanese market, it is necessary to examine its distinct pharmacological profile. Wakefulness and sleep are regulated by complex neurochemical networks in the brain, with the ascending arousal system playing a primary role in maintaining alertness.
Histamine functions not only as a peripheral mediator of allergic and inflammatory responses in the body but also as a vital neurotransmitter in the central nervous system. Histaminergic neurons originate in the tuberomammillary nucleus of the hypothalamus and project widely throughout the brain, promoting wakefulness and cognitive arousal.
In patients with narcolepsy, the loss of hypocretin-producing neurons disrupts these arousal pathways. In patients with OSAS, chronic intermittent hypoxia and fragmented sleep lead to persistent daytime somnolence despite the normalization of nocturnal respiration. Pitolisant acts as an inverse agonist and antagonist at the histamine H3 receptor. By blocking these autoreceptors, pitolisant increases the synthesis and release of histamine in the brain, thereby enhancing the activity of histaminergic wake-promoting pathways.
Because this mechanism does not directly target dopaminergic or amphetamine-like pathways typically utilized by traditional wake-promoting agents, Wakix offers a differentiated safety and tolerability profile. Most notably, its lack of classification as a controlled substance eliminates many of the administrative burdens, prescription limitations, and potential risks of psychological dependence or abuse that clinicians and patients often navigate when managing chronic sleep disorders.
Background and Chronology of Key Events
The journey of pitolisant to the Japanese market is the culmination of years of international research, strategic licensing agreements, and regulatory milestones:
- 1990s–2000s: Bioprojet researchers in Paris discover and characterize pitolisant, identifying the histamine H3 receptor as a viable target for modulating sleep-wake states.
- 2016: Wakix receives its initial approval in the European Union for the treatment of narcolepsy with or without cataplexy.
- 2019: The US Food and Drug Administration (FDA) approves Wakix for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- 2020–2023: Viatris and Bioprojet expand their collaboration, laying the groundwork for clinical development and regulatory submissions in Asia, including Japan. Clinical trials commence to evaluate the drug’s safety and efficacy in Japanese cohorts.
- 2023–2024: Wakix expands its European and international label to include the treatment of excessive daytime sleepiness associated with obstructive sleep apnoea syndrome (OSAS) in numerous countries. Pitolisant is granted orphan drug designation for narcolepsy by Japanese regulatory authorities.
- December 2025: Viatris announces strategic portfolio adjustments, including definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815 million, streamlining its capital allocation toward core therapeutic areas like neurology and sleep medicine.
- September 2026: Japan’s Ministry of Health, Labour and Welfare officially grants marketing authorization to Viatris for Wakix, covering both OSAS-related EDS and narcolepsy types 1 and 2.
Broader Impact on Sleep Medicine and the Japanese Healthcare Landscape
Japan faces unique demographic and public health challenges related to sleep disorders. With one of the world’s oldest populations and high rates of occupational stress and long working hours, chronic sleep deprivation and sleep-related pathologies represent a substantial burden on public health and workplace productivity.
Obstructive sleep apnoea syndrome is highly prevalent among middle-aged and older adults in Japan, often correlating with metabolic syndrome, cardiovascular disease, and hypertension. While continuous positive airway pressure (CPAP) remains the gold standard for treating the underlying anatomical airway obstruction during sleep, clinical data consistently shows that a subset of patients continues to suffer from residual excessive daytime sleepiness even when adherence to CPAP therapy is optimal. This residual somnolence poses ongoing risks for occupational accidents, motor vehicle collisions, and cognitive decline. Wakix provides clinicians with a targeted intervention specifically designed to address this persistent daytime impairment.
Similarly, narcolepsy is a lifelong, debilitating neurological disorder that typically manifests during adolescence or early adulthood, profoundly impacting education, employment, and social functioning. The availability of a non-controlled, histaminergic wake-promoting agent gives Japanese physicians a valuable alternative to older stimulants, which may carry risks of cardiovascular stimulation or dependency.
Economic and Corporate Implications for Viatris
The approval also arrives at an opportune time for Viatris as the company refines its global asset portfolio. Following its strategic transaction in late 2025—which involved divesting its equity stake in Biocon Biologics for $815 million—Viatris has increasingly focused on optimizing its operations and investing in high-margin, differentiated pharmaceutical assets.
The successful commercialization of Wakix in Japan leverages Viatris’ established commercial infrastructure in the region, ensuring that the product can be effectively introduced to neurologists, pulmonologists, sleep specialists, and primary care physicians. Market analysts project that the introduction of a first-in-class therapeutic with orphan drug pedigree will capture significant market share within Japan’s specialized sleep medicine sector.
Future Outlook and Ongoing Clinical Monitoring
Following this regulatory green light, Viatris is expected to collaborate closely with Japanese medical societies, healthcare institutions, and reimbursement authorities to ensure smooth market access and patient uptake. Pricing negotiations with the MHLW will determine the official inclusion of Wakix in the National Health Insurance (NHI) drug tariff, a crucial step preceding commercial launch and broad patient access.
As Wakix enters the Japanese market, post-marketing surveillance studies will be closely monitored by regulatory authorities to gather real-world data on safety, efficacy, and patient adherence across Japanese clinical settings. The accumulation of local real-world evidence will further validate the international clinical trial data and solidify the drug’s position as a foundational element of modern sleep medicine in Japan.
Through this approval, Viatris not only expands its commercial footprint in a strategically vital pharmaceutical market but also delivers an innovative therapeutic solution to thousands of patients burdened by the profound fatigue of narcolepsy and treatment-resistant obstructive sleep apnoea.
